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Abstract 
BACKGROUND: Toxoplasmosis is a zoonotic disease caused by Toxoplasma gondii. Ocular manifestations are 
seen in both congenital and acquired toxoplasmosis. These can include focal inflammation within or around the 
optic nerve head (papillitis). Purpose of this study is evaluating the efficacy of systemic steroid in HIV patient with 
toxoplasma papillitis.  
CASE PRESENTATION: We present a case report of a male, 46 years old with a decrease of visual acuity on the 
right eye for three weeks before admission to the hospital. An ophthalmology examination showed visual acuity of 
the right eye 1/60, mild dilatation of the pupil and posterior synechiae, vitreous was hazy, and fundus examination 
showed optic nerve head not well demarcated and hyperaemic with the good retina and macula reflex. Laboratory 
examination showed reactive anti-Toxoplasma immunoglobulin G. Patient had been treated with antiretroviral and 
anti-Toxoplasma drugs, then he was given steroid 250 mg intravenously four times per day for three days and 
tapering off orally. Visual acuity on the right eye improve from 1/60 became 6/60 after use of steroid on the third 
day.  
DISCUSSION: Steroid can improve visual acuity for toxoplasma papillitis in this patient. But the long term and 
close follow up in steroid therapy is needed. 
 
 
 
 
 
 
Introduction 
 
Toxoplasmosis is a chronic disease caused 
by Toxoplasma gondii infection, which is an obligate 
intracellular parasite. The most common manifestation 
of Toxoplasma in HIV-infected patients is cerebral 
toxoplasma, whereas the most common extracerebral 
manifestations can be ocular and lungs diseases [1], 
[2], [3], [4], [5]. 
An ocular manifestation of toxoplasma can be 
in congenital or acquired. Some rare manifestations 
include papillitis, neuroretinitis, retrobulbar neuritis, 
central serous retinopathy, and scleritis. Toxoplasma 
papillitis mostly unilateral, and there is no predilection 
of gender. Clinical symptoms that appear in the form 
of blurry vision, red eyes, pain, and systemic 
symptoms such as fever and weakness [6], [7], [8], 
[9], [10].  
Administration of steroids in Toxoplasma 
papillitis expected to suppress inflammation and use 
with caution due to its immunosuppression effect. 
Although still controversial, the administration of 
steroids has significant benefits for the inflammatory 
process. Therapy with steroids is not required in 
ocular management of Toxoplasma, but steroids are 
used as adjunctive therapy in ocular toxoplasma [3], 
[9], [11], [12], [13], [14]. 
Management of Toxoplasma papillitis in HIV-
infected patients is quite difficult, so it requires 
multidisciplinary to determine the type of therapy. The 
goal of this case report is to evaluate the efficacy of 
systemic steroid use for HIV-infected patients with 
Toxoplasma papillitis, so it would be better 
management for similar cases. 
Case Report 
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Case Presentation 
 
A 46-years old, bisexual, male patient came 
with initial presentation blurry vision on the right eye 
since a year ago and became worse since the last 3 
weeks. It felt like a worse sensation when the eyes 
were moving — the history of red eyes since a year 
ago and recurrence. The symptoms had been treated 
by an ophthalmologist. The patient was diagnosed 
with HIV and toxoplasmosis since a year ago and 
undergoing treatment. 
General assessment on the normal limit. 
Ophthalmology examination on the right eye was 
found visual acuity 1/60 and not improved with 
pinhole, palpebral was normal, hyperemic conjunctiva, 
mild dilatation, pupil posterior synechiae, vitreous 
opacities, optic nerve head hyperemic and not well 
demarcated. 
The intraocular pressure was normal. The eye 
movement was good in all direction. There was a 
defect Confrontation visual field test.  
 
Figure 1: Anterior segment on the right eye 
 
There was no a specific defect on the colour 
vision test and decreasing of contrast sensitivity 
(0.75). The Optical Coherence Tomography (OCT) 
examination showed inferior and temporal thickening, 
cup-disc ratio 1.00 as result of OCT Optic Nerve 
Head. 
 
Figure 2: Fundus photography on the right eye (left) and left eye 
(right) 
 
Laboratory tests showed an increase in 
erythrocyte sedimentation rate, decreased CD-4 
levels to 201, reactive anti-toxoplasma 
immunoglobulin G with titers 58, reactive anti-rubella 
immunoglobulin G, reactive anti-HSV 1 and 2 
immunoglobulin G. 
 
Figure 3: Optical Coherence Tomography (OCT) (RNFL) on the 
right eye 
 
 The patient was diagnosed with right eye 
Toxoplasma Papillitis and consulted to the neuro-
ophthalmology and internal medicine for the plan to 
administer Optic Neuritis Treatment Trial (ONTT). The 
patient was diagnosed with stage IV HIV infection by 
internal medicine and given anti-toxoplasma treatment 
(cotrimoxazole and clindamycin), anti-retroviral and 
had been done the ONTT for three days by 
methylprednisolone 250 mg four times per day 
intravenously, mecobalamin 500 mg three times per 
day orally, and antacids three times per day orally. 
 
Figure 4: Optical Coherence Tomography (OCT) ONH on the right 
eye  
 
Day forth of treating with ONTT, the patient 
still complained of nausea and dizziness, but the 
vision was getting better. Visual acuity of right eye 
6/60 pinhole NI, normal palpebra, normal conjunctiva, 
clear cornea, deep ocular anterior chamber, iris and 
pupil dilated, there are posterior synechiae, cloudy 
vitreous, fundus examination is obtained by optic 
nerve head indeterminate hyperemia boundary with 
the normal retina and positive macular reflex. 
Intraocular pressure was normal — eyeball movement 
in all directions. Confrontation test of the right eye is 
disturbed. The patient was diagnosed with toxoplasma 
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papillitis and stage IV HIV infection. Tapering off 
intravenous methylprednisolone have been done and 
then replaced with oral methylprednisolone 32 mg 
twice per day, mecobalamin 500 mg three times per 
day orally, and antacids three times per day orally, 
anti-toxoplasma (cotrimoxazole and clindamycin) and 
antiretrovirals continued. The patient was allowed to 
go home and suggested to control one week later, but 
patients do not come for treatment. 
 
 
Discussion 
 
Toxoplasma papillitis is a rare manifestation 
of Toxoplasma, usually unilateral and does not have a 
predilection of gender. Clinical symptoms such as 
blurry vision, red eyes, pain, also causing systemic 
fever and general weakness [6], [10]. 
Toxoplasma gondii was first discovered in 
1908 in the brains of South African rats and caused 
ocular disease for the first time in 1923. Transmission 
of Toxoplasma gondii by ingesting food containing 
oocysts, transplacental, through mucous membranes, 
after a blood transfusion or organ transplantation. 
Toxoplasma encephalitis is a manifestation of 
Toxoplasma in HIV-infected patients, but 
extracerebral manifestations can occur with or without 
encephalitis. The most common extracerebral 
manifestations can be ocular or pulmonary disease 
[3], [4], [9]. 
The transmission of Toxoplasma gondii by 
hematogenous and mostly affects the retinal vascular 
endothelial cells, so most of them manifest as retinitis 
with complaints of decreased visual acuity. Other 
manifestations can be vitreous and anterior uveitis. In 
severe vitreous can develop into epiretinal membrane 
and traction, headlight in the fog is found on fundus 
examination. Rare manifestations such as 
inflammation by Toxoplasma in the optic nerve head 
with hyperemia fundus images on the optic nerve 
head [3], [6], [9], [10]. 
The diagnosis of toxoplasma papillitis 
confirmed through fundal examination and supporting 
clinical features. If the clinical diagnosis cannot be 
confirmed through fundus examination, supporting 
examination such as increased detection of 
Toxoplasma gondii antibody titers in eye fluids or 
Toxoplasma gondii DNA and antibody tests in the 
blood [3], [6], [9], [10]. 
Management of Toxoplasma papillitis requires 
anti-parasitic combination such as pyrimethamine, 
sulfadiazine, clindamycin or azithromycin. These anti-
parasitic therapies are effective for stopping the 
multiplication of parasites but cannot eliminate 
parasites from the human body. Administration of 
steroids in Toxoplasma papillitis should be adjunctive 
because it can suppress the immune response. A 
case report stated, there are improvement visual 
acuity of ocular toxoplasma after prednisone 1 mg/kg. 
A study stated steroid administration begins within 
three days or a week after anti-toxoplasma therapy 
[6], [14], [15], [16], [17]. 
The use of steroids in good observation 
expected to suppress inflammation and reduce injury 
of ocular tissue, but the overall outcome is still 
uncertain. Steroids can cause side effects such as 
abdominal pain, bloating/flatulence, nausea, 
dizziness, joint pain, menstrual disorders, weight gain 
and increased appetite [18]. 
The visual acuity of patients after 
administration of steroid improved from 1/60 to 6/60, 
but patients complained of nausea and dizziness after 
administration of the steroid.  
In conclusion, there have been reported 
cases of Toxoplasma papillitis in an HIV-infected 
patient who showed improvement in visual acuity after 
given systemic steroid therapy for three days. Further 
studies are needed to determine the efficacy and side 
effects of short-term systemic steroid use in HIV 
cases with Toxoplasma papillitis. 
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